Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
2020年11月24日 更新者：Eli Lilly and Company
A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma
The purpose is to assess the efficacy and toxicity of the study agent, enzastaurin, in participants with recurrent or persistent ovarian cancer.
調査の概要
研究の種類
介入
入学 (実際)
28
段階
- フェーズ2
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19103
- Gynecologic Oncology Group 215-854-0770
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
女性
説明
Inclusion Criteria:
- Participants must have recurrent or persistent epithelial ovarian or primary peritoneal carcinoma.
- All participants must have measurable disease.
- Participants must have at least one "target lesion" to be used to assess response on this protocol.
- Participants must not be eligible for a higher priority GOG protocol, if one exists.
- Participants who have received one prior regimen must have a GOG Performance Status of 0, 1, or 2. Participants who have received two prior regimens must have a GOG Performance Status of 0 or 1.
- Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Continuation of hormone replacement therapy is permitted.
- Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least four weeks prior to registration.
- Participants must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound.
- Participants must NOT have received any non-cytotoxic therapy for management of recurrent or persistent disease.
- Participants of child-bearing potential must have a negative serum pregnancy test prior to study entry and be practicing an effective form of contraception (for example, intrauterine device [IUD], birth control pills, or barrier device) during and for 3 months after discontinuation of study treatment.
Exclusion Criteria:
- Participants with previous enzastaurin treatment.
- Participants who have received radiation to more than 25% of marrow-bearing areas
- Participants with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy.
- Participants who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- Participants who are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin (refer to Concomitant Medications for a discussion of enzyme inducing anti-epileptic drugs [EIAEDs]).
- Participants who are receiving concurrent administration of any other systemic anticancer therapy except for a biphosphonate if patient has bony metastases.
- Participants who have received prior therapy with non-cytotoxic agents (i.e. bevacizumab).
- Participants with serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：順次割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：あ
|
1125 mg loading dose then 500 mg, oral, daily, until progressive disease
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free Survival for at Least 6 Months (PFS-6)
時間枠：Baseline through 6 months
|
Data presented are the percentage of participants without progressive disease (PD) or death from any cause 6 months after registration.
PD was a 25% increase in the sum of products of all measurable lesions (or 2 largest lesions if too numerous) over the smallest sum observed (over baseline if no decrease) or clear worsening of any evaluable disease, or appearance of any new lesion/site, or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
|
Baseline through 6 months
|
|
Number of Participants With Adverse Events and Severe Adverse Events
時間枠：Baseline through end of study (Up to 45 months)
|
Data presented are the number of participants who experienced 1 or more adverse events (AEs) (all causalities and drug-related) and serious AEs (SAEs).
A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.
|
Baseline through end of study (Up to 45 months)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of Progression-Free Survival
時間枠：Baseline to disease progression (Up to 38 months)
|
PFS is defined as the rate of PFS from the date of diagnosis to the first date of objectively determined progressive disease (based on radiological assessment) or death from any cause.
It is assumed that PFS follows an exponential distribution.
|
Baseline to disease progression (Up to 38 months)
|
|
Prognostic Factors: Platinum Sensitivity
時間枠：Baseline
|
Participants who had disease progression within 6 months of ending their last regimen of platinum therapy were considered platinum resistant.
Participants who had disease progression between 6 and 12 months of ending their last platinum regimen were considered platinum sensitive.
Participants who had disease progression beyond 12 months of ending their last platinum regimen were also considered platinum sensitive.
|
Baseline
|
|
Prognostic Factors: Performance Status
時間枠：Baseline
|
Performance Status 0 = Fully active, able to carry on all pre-disease performance without restriction Performance Status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work.
|
Baseline
|
|
Overall Survival
時間枠：Baseline through end of study (Up to 45 months)
|
Overall survival (OS) time is defined as the time from the date of diagnosis to the date of death from any cause.
For participants who are still alive at the time of analysis, survival time will be censored at the last contact date.
|
Baseline through end of study (Up to 45 months)
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- スタディディレクター：Lydia Usha、Gynecologic Oncology Group
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2007年1月1日
一次修了 (実際)
2008年5月1日
研究の完了 (実際)
2014年12月1日
試験登録日
最初に提出
2007年1月8日
QC基準を満たした最初の提出物
2007年1月8日
最初の投稿 (見積もり)
2007年1月11日
学習記録の更新
投稿された最後の更新 (実際)
2020年12月19日
QC基準を満たした最後の更新が送信されました
2020年11月24日
最終確認日
2020年11月1日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 10738
- H6Q-MC-S025 (その他の識別子：Eli Lilly and Company)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。